PE20210405A1 - Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2) - Google Patents

Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2)

Info

Publication number
PE20210405A1
PE20210405A1 PE2021000013A PE2021000013A PE20210405A1 PE 20210405 A1 PE20210405 A1 PE 20210405A1 PE 2021000013 A PE2021000013 A PE 2021000013A PE 2021000013 A PE2021000013 A PE 2021000013A PE 20210405 A1 PE20210405 A1 PE 20210405A1
Authority
PE
Peru
Prior art keywords
alkyl
oxoisoindolin
piperidine
family
haloalkyl
Prior art date
Application number
PE2021000013A
Other languages
English (en)
Inventor
Claire Adcock
Simone Bonazzi
Artiom Cernijenko
Philip Lam
Kathryn Taylor Linkens
Hasnain Ahmed Malik
Michael Scott Visser
Noel Marie-France Thomsen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20210405A1 publication Critical patent/PE20210405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

Un compuesto de la Formula (I'), donde: X1 y X2 son H, (C1-C4)alquilo, (C1-C6)alcoxi, (C1-C4)haloalquilo, (C1-C6)haloalcoxi, (C3-C7)cicloalquilo, halogeno, -CN, -OH, o -NH2; Rx es H o D; R1 es a) o b); R2 es (C1-C6)alquilo, (C1-C6)alcoxi, (C1-C6)haloalquilo, entre otros; R3 es (C1-C6)alquilo, (C1-C6)alcoxi, (C1-C6)haloalquilo, (C1-C6)haloalcoxi, halogeno, -OH, o -NH2; R4 es -OR5 o -NR6R6'; R5 es H, (C1-C6)alquilo, (C1-C6)haloalquilo, (C3-C7)cicloalquilo, heterocicloalquilo de 5 o 6 miembros que comprende 1-3 heteroatomos seleccionados entre O, N, y S, (C6-C10)arilo, o heteroarilo de 5 o 6 miembros que comprende 1-3 heteroatomos seleccionados entre O, N, y S, en donde el alquilo es opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre (C6-C10)arilo y heteroarilo de 5 o 6 miembros que comprende 1-3 heteroatomos seleccionados entre O, N, y S; R6 y R6' son H, (C1-C6)alquilo, (C1-C6)haloalquilo, (C2-C6)hidroxialquilo, entre otros; m y m1 son 0, 1 o 2; n1 es 0, 1, 2, o 3; y cada s y n son 1, 2, o 3. Son compuestos preferidos: 3-(5-(((1R,2R)-2-((2,2-difluoroetil)(etil)amino)ciclopentil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona; 3-(5-((2-((2,2-difluoroetil)(etil)amino)ciclopentil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona; 3-(5-(((1S,2R)-2-(bencilamino)ciclohexil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona; entre otros. Dichos compuestos tienen actividad sobre la proteina con dedos de zinc 2 de la Familia IKAROS (IKZF2) y son utiles en el tratamiento de cancer y enfermedades relacionadas
PE2021000013A 2018-07-10 2019-07-08 Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2) PE20210405A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695920P 2018-07-10 2018-07-10
US201962835543P 2019-04-18 2019-04-18
PCT/IB2019/055804 WO2020012334A1 (en) 2018-07-10 2019-07-08 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases

Publications (1)

Publication Number Publication Date
PE20210405A1 true PE20210405A1 (es) 2021-03-02

Family

ID=68136441

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000013A PE20210405A1 (es) 2018-07-10 2019-07-08 Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2)

Country Status (32)

Country Link
US (2) US11192877B2 (es)
EP (2) EP4306111A3 (es)
JP (1) JP2021524484A (es)
KR (1) KR20210031680A (es)
CN (1) CN112261970A (es)
AU (1) AU2019301944B2 (es)
BR (2) BR122022012697B1 (es)
CA (1) CA3103385A1 (es)
CL (1) CL2021000038A1 (es)
CO (1) CO2021000078A2 (es)
CR (1) CR20210001A (es)
CU (1) CU20210002A7 (es)
DK (1) DK3820573T3 (es)
EC (1) ECSP21000990A (es)
ES (1) ES2963694T3 (es)
FI (1) FI3820573T3 (es)
HR (1) HRP20231295T1 (es)
HU (1) HUE063715T2 (es)
IL (1) IL278951B (es)
JO (1) JOP20210001A1 (es)
LT (1) LT3820573T (es)
MX (1) MX2021000309A (es)
PE (1) PE20210405A1 (es)
PH (1) PH12021550045A1 (es)
PL (1) PL3820573T3 (es)
PT (1) PT3820573T (es)
RS (1) RS64759B1 (es)
SA (1) SA521420985B1 (es)
SG (1) SG11202011872QA (es)
SI (1) SI3820573T1 (es)
UY (1) UY38297A (es)
WO (1) WO2020012334A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CN110331124B (zh) * 2019-06-14 2022-03-22 浙江大学 一种导电聚吡咯/细胞外基质复合薄膜及其制备方法
IL293027A (en) 2019-11-19 2022-07-01 Bristol Myers Squibb Co Compounds useful as inhibitors of Helios protein
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
CN113005151A (zh) * 2021-03-12 2021-06-22 广东药科大学 一种kdr-car-nk细胞的制备方法及其应用
WO2022216644A1 (en) 2021-04-06 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
BR112023024905A2 (pt) * 2021-06-03 2024-02-20 Novartis Ag Derivados de 3-(5-oxoisoindolin-2-il)piperidina-2,6-diona e seus usos
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023283430A1 (en) * 2021-07-09 2023-01-12 Plexium, Inc. Cycloalkyl compounds and pharmaceutical compositions that modulate ikzf2
WO2023283428A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Heterocycloalkyl and heteroaryl compounds and pharmaceutical compositions that modulate ikzf2
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US7196170B2 (en) 1992-09-14 2007-03-27 The General Hospital Corporation Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
WO2002044372A2 (en) 2000-12-01 2002-06-06 Parker Hughes Institute Nucleotide and protein sequence of helios 3 and methods of use
NZ531294A (en) 2001-08-06 2005-11-25 Childrens Medical Center Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
ES2485841T3 (es) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
MXPA04008722A (es) 2002-03-08 2005-07-13 Eisai Co Ltd Compuestos macrociclicos utiles como farmaceuticos.
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
EP1715882A4 (en) 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
US20070161696A1 (en) 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP1778718B1 (en) 2004-07-02 2014-10-08 Genentech, Inc. Inhibitors of iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
MX2007000490A (es) 2004-07-12 2007-06-11 Idun Pharmaceuticals Inc Analogos de tetrapeptido.
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
MX2007002521A (es) 2004-09-03 2007-05-09 Celgene Corp Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
CN101111234A (zh) 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
EP1824997B1 (en) 2004-12-10 2010-09-15 Siemens Healthcare Diagnostics GmbH Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP1974013A2 (en) 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
KR101342035B1 (ko) 2006-06-20 2013-12-16 한국과학기술연구원 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
AU2008229383B2 (en) * 2007-03-20 2013-09-05 Celgene Corporation 4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN101687787A (zh) 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
RU2523890C2 (ru) 2007-09-12 2014-07-27 Дженентек, Инк. Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2227558A1 (en) 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
KR100957051B1 (ko) 2007-12-28 2010-05-13 한국과학기술연구원 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
GB2456390A (en) 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
NZ592425A (en) 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
IN2012DN01920A (es) 2009-09-03 2015-07-24 Schering Corp
CA2778005A1 (en) 2009-10-26 2011-05-12 Abbott Laboratories Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
RS59275B1 (sr) 2010-02-11 2019-10-31 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
AU2011253481A1 (en) 2010-05-12 2013-01-10 Steven E. Schutzer Diagnostic markers for neuropsychiatric disease
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012021867A2 (en) 2010-08-13 2012-02-16 The Johns Hopkins University A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors
AU2011317211B2 (en) 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
US9295664B2 (en) 2011-06-06 2016-03-29 University Of Iowa Research Foundation Methods for lowering blood glucose
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
WO2013006474A2 (en) 2011-07-01 2013-01-10 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN103797120B (zh) 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
CN108676774B (zh) 2011-12-01 2023-05-09 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
US9481866B2 (en) 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
IN2014CN04935A (es) 2011-12-31 2015-09-18 Moni Abraham Kuriakose
CA2866116C (en) 2012-03-02 2021-06-15 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory t cells
GB201207297D0 (en) 2012-04-26 2012-06-06 Senzagen Ab Analytical methods and arrays for use in the same
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
EP2682750A1 (en) 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP6403166B2 (ja) 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
BR112015005243A2 (pt) 2012-09-10 2017-07-04 Celgene Corp métodos para o tratamento de câncer de mama localmente avançado
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2953524B1 (en) 2013-02-06 2018-08-01 Freenome Holdings Inc. Systems and methods for early disease detection and real-time disease monitoring
WO2014153115A2 (en) 2013-03-14 2014-09-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
PE20151530A1 (es) 2013-03-15 2015-11-06 Glaxosmithkline Ip Dev Ltd Proteinas de union a antigeno
CN105378104A (zh) 2013-03-15 2016-03-02 威拉赛特公司 用于样品分类的方法和组合物
LT2992017T (lt) 2013-05-02 2021-02-25 Anaptysbio, Inc. Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US20160122821A1 (en) 2013-06-10 2016-05-05 Suregene, Llc Genetic markers of antipsychotic response
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB2532672A (en) 2013-09-09 2016-05-25 Scripps Research Inst Methods and systems for analysis of organ transplantation
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
WO2015050875A1 (en) 2013-10-01 2015-04-09 The Regents Of The University Of California Endometriosis classifier
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
ME03527B (me) 2013-12-12 2020-04-20 Shanghai hengrui pharmaceutical co ltd Pd-1 antitijelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primjena
PL3094351T3 (pl) 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016009010A (es) 2014-01-28 2017-01-18 Bristol Myers Squibb Co Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas.
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
MX2016011993A (es) 2014-03-14 2016-12-09 Novartis Ag Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
CN106458993A (zh) 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
IL249092B (en) 2014-05-28 2022-07-01 Agenus Inc Anti-gitr antibodies and methods of using them
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MX2017004311A (es) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
PL3643709T3 (pl) 2014-10-30 2022-02-21 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, jej związek pośredni, sposób wytwarzania, kompozycja farmaceutyczna i zastosowanie
KR102011205B1 (ko) 2014-11-06 2019-08-14 에프. 호프만-라 로슈 아게 항-tim3 항체 및 사용 방법
US11959141B2 (en) 2014-12-05 2024-04-16 Foundation Medicine, Inc. Multigene analysis of tumor samples
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016209321B2 (en) 2015-01-20 2019-05-09 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
EP3050570A1 (en) 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
WO2016140974A1 (en) 2015-03-01 2016-09-09 Novena Therapeutics Inc. Process for measuring tumor response to an initial oncology treatment
EP3265486A4 (en) 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
JP6629885B2 (ja) 2015-05-22 2020-01-15 バイオセリックス， インコーポレイテッド タンパク質を標的とする化合物、その組成物、方法、および使用
EP3304076A4 (en) 2015-06-02 2018-12-19 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
EP3302548A4 (en) 2015-06-03 2019-01-02 Dana Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JP6812364B2 (ja) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌診断用抗ｇｉｔｒ抗体
CN108136044B (zh) 2015-06-04 2021-08-10 阿尔维纳斯运营股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
EA201890097A1 (ru) 2015-06-22 2018-07-31 Президент Энд Феллоуз Оф Гарвард Колледж Индукция регуляторных т-клеток lamina propria
WO2017015623A2 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
WO2017025610A1 (en) 2015-08-12 2017-02-16 Medimmune Limited Gitrl fusion proteins and uses thereof
WO2017042337A1 (en) 2015-09-09 2017-03-16 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft Short-chain fatty acids for use in the treatment of cardiovascular disease
WO2017044979A2 (en) 2015-09-11 2017-03-16 Ventria Bioscience Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2017059062A1 (en) 2015-09-30 2017-04-06 Theunited States Of America, As Represented By The Secretary, Department Of Health And Human Service Thalidomide analogs and methods of use
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3384013A4 (en) 2015-12-04 2019-07-10 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. T-CELLS SPECIFIC TO ANTIGEN TO INDUCE IMMUNE TOLERANCE
DK3429603T3 (da) 2016-03-15 2022-03-14 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
WO2017176958A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
WO2018102067A2 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
CA3042968C (en) 2016-12-01 2023-10-17 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR102582886B1 (ko) 2017-01-26 2023-09-26 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN106932576A (zh) 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
EP3697436A1 (en) 2017-10-18 2020-08-26 Novartis AG Compositions and methods for selective protein degradation
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos

Also Published As

Publication number Publication date
MX2021000309A (es) 2021-04-12
WO2020012334A1 (en) 2020-01-16
CO2021000078A2 (es) 2021-01-18
BR122022012697B1 (pt) 2023-04-04
PL3820573T3 (pl) 2024-02-19
EP4306111A2 (en) 2024-01-17
TW202012387A (zh) 2020-04-01
PH12021550045A1 (en) 2021-09-20
BR112020026947A2 (pt) 2021-03-30
ECSP21000990A (es) 2021-03-31
SA521420985B1 (ar) 2023-02-19
CR20210001A (es) 2021-04-19
IL278951A (en) 2021-01-31
AU2019301944B2 (en) 2022-02-24
SG11202011872QA (en) 2021-01-28
KR20210031680A (ko) 2021-03-22
US20230067476A1 (en) 2023-03-02
JOP20210001A1 (ar) 2021-01-05
CA3103385A1 (en) 2020-01-16
BR112020026947B1 (pt) 2022-11-22
EP3820573A1 (en) 2021-05-19
CL2021000038A1 (es) 2021-07-30
JP2021524484A (ja) 2021-09-13
PT3820573T (pt) 2023-10-30
EP3820573B1 (en) 2023-08-09
RS64759B1 (sr) 2023-11-30
SI3820573T1 (sl) 2023-12-29
ES2963694T3 (es) 2024-04-01
IL278951B (en) 2022-08-01
US11192877B2 (en) 2021-12-07
US20200017461A1 (en) 2020-01-16
UY38297A (es) 2020-02-28
CN112261970A (zh) 2021-01-22
AU2019301944A1 (en) 2020-12-24
CU20210002A7 (es) 2021-08-06
HRP20231295T1 (hr) 2024-02-02
HUE063715T2 (hu) 2024-01-28
EP4306111A3 (en) 2024-04-17
DK3820573T3 (da) 2023-10-23
LT3820573T (lt) 2023-11-10
FI3820573T3 (fi) 2023-11-01

Similar Documents

Publication Publication Date Title
PE20210405A1 (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2)
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
CL2021003022A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar enfermedad de huntington (div. sol. 202003378).
RU2009133472A (ru) Пиримидин-замещенные макроциклические ингибиторы hcv
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20141702A1 (es) Compuestos de carbamato y preparacion y uso de los mismos
AR074790A1 (es) Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR102171A1 (es) Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR061842A1 (es) Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteina quinasa akt
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR048834A1 (es) Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5)
AR069513A1 (es) Derivados de amidas del acido 6,7-dihidro -5h-imidazo¿1,2-alfa]imidazol-3-carboxilico, y composiciones farmaceuticas que los contienen
EA201190119A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla